ANTI-IL-6 ANTIBODY CLAZAKIZUMAB IN LATE ANTIBODY-MEDIATED REJECTION - MOLECULAR REBOUND PHENOMENA UNDER IL-6 BLOCKADE?

被引：0
|
作者：
Borski, Anita [1 ]
Haindl, Susanne [2 ]
Durr, Michael [3 ]
Budde, Klemens [3 ]
Schranz, Sabine [1 ]
Eskandary, Farsad A. [2 ]
Doberer, Konstantin [2 ]
Halloran, Philip F. [4 ]
Chong, Edward [5 ]
Jilma, Bernd [1 ]
Bohmig, Georg A. [2 ]
Wahrmann, Markus [2 ]
机构：
[1] Med Univ Vienna, Dept Clin Pharmacol, Vienna, Austria
[2] Med Univ Vienna, Dept Med 3, Vienna, Austria
[3] Charite Univ Med Berlin, Dept Nephrol & Med Intens Care, Berlin, Germany
[4] Univ Alberta, Dept Med, Edmonton, AB, Canada
[5] Vitaeris Inc, Vancouver, BC, Canada
来源：
TRANSPLANTATION | 2020年 / 104卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
380.1
引用
收藏
页码：S67 / S67
页数：1
相关论文
共 50 条
  • [21] Increase in serum levels of IL-6 and soluble IL-6 receptor after anti-IL-6 receptor antibody therapy in patients with rheumatoid arthritis
    Nishimoto, N
    Terao, K
    Kakehi, T
    Kishimoto, T
    ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S109 - S110
  • [22] INCREASED CIRCULATING INTERLEUKIN-6 (IL-6) ACTIVITY IN ENDOTOXIN-CHALLENGED MICE PRETREATED WITH ANTI-IL-6 ANTIBODY IS DUE TO IL-6 ACCUMULATED IN ANTIGEN-ANTIBODY COMPLEXES
    MARTENS, E
    DILLEN, C
    PUT, W
    HEREMANS, H
    VANDAMME, J
    BILLIAU, A
    EUROPEAN JOURNAL OF IMMUNOLOGY, 1993, 23 (08) : 2026 - 2029
  • [23] Monitoring Inflammatory Cytokine Levels in Kidney Transplant Patients (KTx Pts) with Chronic Antibody Mediated Rejection (cABMR) Treated with Clazakizumab (CLZ, Humanized Anti-IL-6 Monoclonal Antibody).
    Ge, S.
    Petrosyan, A.
    Chu, M.
    Ammerman, N.
    Vo, A.
    Jordan, S. C.
    Zhang, X.
    Toyoda, M.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2019, 19 : 661 - 661
  • [24] CLAZAKIZUMAB Humanized Anti-IL-6 Monoclonal Antibody Treatment of Rheumatoid Arthritis Treatment of Autoimmune Diseases Oncolytic
    Reviriego, C.
    DRUGS OF THE FUTURE, 2012, 37 (09) : 633 - 636
  • [25] A novel anti-IL-6 monoclonal antibody leads to restoration of IL-6-mediated endothelial barrier breakdown
    Feenstra, Derrick
    Strassburger, Pamela
    Widmer, Gabriella
    Revelant, Franco
    Uhles, Sabine
    Hinner, Marlon
    Meier, Anastasia
    Lazendic, Mirjana
    Gruener, Sabine
    Fauser, Sascha
    Mesquida, Marina
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2023, 64 (08)
  • [26] Blockade of IL-6/IL-6R Signaling Attenuates Acute Antibody-Mediated Rejection in a Mouse Cardiac Transplantation Model (vol 12, 778359. 2021)
    Ma, Maolin
    Sun, Qipeng
    Li, Xiujie
    Deng, Gengguo
    Zhang, Yannan
    Yang, Zhe
    Han, Fei
    Huang, Zhengyu
    Fang, Youqiang
    Liao, Tao
    Sun, Qiquan
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [27] Anti-interleukin-6 antibody clazakizumab in late antibody-mediated kidney transplant rejection: effect on cytochrome P450 drug metabolism
    Muehlbacher, Jakob
    Schoergenhofer, Christian
    Doberer, Konstantin
    Duerr, Michael
    Budde, Klemens
    Eskandary, Farsad
    Mayer, Katharina A.
    Schranz, Sabine
    Ely, Sarah
    Reiter, Birgit
    Chong, Edward
    Adler, Scott H.
    Jilma, Bernd
    Boehmig, Georg A.
    TRANSPLANT INTERNATIONAL, 2021, 34 (08) : 1542 - 1552
  • [28] Anti-IL-6 receptor antibody therapy for autoimmune diseases
    Ishikawa, N. Nishimoto.
    Lee, H.
    Aoki, C.
    Mima, T.
    ARCHIVES OF DERMATOLOGICAL RESEARCH, 2009, 301 (01) : 44 - 44
  • [29] Protective effects of anti-IL-6 antibody treatment in sepsis
    Neff, TA
    Riedemann, NC
    Guo, RF
    Laudes, I
    Sarma, V
    Ward, PA
    FASEB JOURNAL, 2002, 16 (04): : A592 - A592
  • [30] Effects of anti-IL-6 receptor antibody on human monocytes
    Tono, Toshihiro
    Aihara, Satoko
    Hoshiyama, Takayuki
    Arinuma, Yoshiyuki
    Nagai, Tatsuo
    Hirohata, Shunsei
    MODERN RHEUMATOLOGY, 2015, 25 (01) : 79 - 84
12345